[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1257632T3 - Samtidig stimulering og opkoncentrering af celler - Google Patents

Samtidig stimulering og opkoncentrering af celler

Info

Publication number
DK1257632T3
DK1257632T3 DK01916241T DK01916241T DK1257632T3 DK 1257632 T3 DK1257632 T3 DK 1257632T3 DK 01916241 T DK01916241 T DK 01916241T DK 01916241 T DK01916241 T DK 01916241T DK 1257632 T3 DK1257632 T3 DK 1257632T3
Authority
DK
Denmark
Prior art keywords
cells
cell surface
cell
surface moiety
methods
Prior art date
Application number
DK01916241T
Other languages
English (en)
Inventor
Ron Berenson
Mark Bonyhadi
Narinder Saund
Stewart Craig
Dale Kalamasz
Alan Hardwick
David Mcmillen
Che Law
Original Assignee
Xcyte Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xcyte Therapies Inc filed Critical Xcyte Therapies Inc
Application granted granted Critical
Publication of DK1257632T3 publication Critical patent/DK1257632T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/53—CD2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/12—Glass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/14—Ceramic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/18—Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/72—Chitin, chitosan
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK01916241T 2000-02-24 2001-02-26 Samtidig stimulering og opkoncentrering af celler DK1257632T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18478800P 2000-02-24 2000-02-24
US24990200P 2000-11-17 2000-11-17
PCT/US2001/006139 WO2001062895A2 (en) 2000-02-24 2001-02-26 Simultaneous stimulation and concentration of cells

Publications (1)

Publication Number Publication Date
DK1257632T3 true DK1257632T3 (da) 2008-01-28

Family

ID=26880473

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01916241T DK1257632T3 (da) 2000-02-24 2001-02-26 Samtidig stimulering og opkoncentrering af celler

Country Status (16)

Country Link
US (1) US6905874B2 (da)
EP (1) EP1257632B1 (da)
JP (1) JP2004500095A (da)
KR (1) KR20030032922A (da)
CN (1) CN1419597A (da)
AT (1) ATE373078T1 (da)
AU (2) AU4328801A (da)
BR (1) BR0108545A (da)
CA (1) CA2406864A1 (da)
DE (1) DE60130435T2 (da)
DK (1) DK1257632T3 (da)
ES (1) ES2302726T3 (da)
HK (2) HK1047770A1 (da)
IL (2) IL151287A0 (da)
MX (1) MXPA02008265A (da)
WO (1) WO2001062895A2 (da)

Families Citing this family (603)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
AU2002232560A1 (en) * 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
US20020055759A1 (en) * 2000-11-06 2002-05-09 Shibuya Terry Y. Bioactive surgical suture
KR20030059314A (ko) * 2000-12-07 2003-07-07 알타나 파마 아게 산 불안정성 활성 성분을 포함하는 페이스트 형태의 약학제제
US7638326B2 (en) * 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
AU2003202908A1 (en) * 2002-01-03 2003-07-24 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
CA2474186A1 (en) * 2002-02-08 2003-08-14 Xcyte Therapies, Inc. Compositions and methods for restoring immune responsiveness in patients with immunological defects
CN100379852C (zh) * 2002-02-08 2008-04-09 埃克斯西特治疗公司 用于在免疫缺陷患者体内恢复免疫响应的组合物和方法
DE10212108A1 (de) * 2002-03-13 2003-10-02 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
EA010434B1 (ru) 2002-03-25 2008-08-29 Такара Био Инк. Способ получения цитотоксических лимфоцитов
CA2490401A1 (en) * 2002-06-28 2004-01-08 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
DE10230223A1 (de) * 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
EP1581637A4 (en) * 2002-11-07 2007-04-25 Univ Chicago MATERIALS AND METHODS WITH HUMAN STEM CELLS
CN1230531C (zh) * 2002-12-09 2005-12-07 清华大学 从样品中分离细胞粒子的方法
WO2004075855A2 (en) 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
US20040224402A1 (en) * 2003-05-08 2004-11-11 Xcyte Therapies, Inc. Generation and isolation of antigen-specific T cells
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US20070025961A1 (en) * 2003-06-03 2007-02-01 Kenzo Bamba Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf
EP1666589B1 (en) 2003-08-22 2010-02-17 Takara Bio Inc. Process for producing cytotoxic lymphocytes
CA2539716A1 (en) * 2003-09-22 2005-04-07 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery
WO2005069001A1 (ja) * 2003-09-25 2005-07-28 Toyama Prefecture マイクロウェルアレイチップ及びその製造方法
US20090118817A1 (en) * 2005-06-16 2009-05-07 Mayo Foundation For Medical Education And Research Magnetic Medical Apparatus, Kits, and Methods
US8465453B2 (en) * 2003-12-03 2013-06-18 Mayo Foundation For Medical Education And Research Kits, apparatus and methods for magnetically coating medical devices with living cells
EP1715889A4 (en) * 2004-01-08 2008-03-05 Univ California REGULATORY T CELLS SUPPRESS AUTOIMMUNITY
EP2573166B1 (en) 2004-02-26 2016-05-11 Immunovative Therapies, Ltd. Methods for preparing T-cells for cell therapy
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
JP5070045B2 (ja) 2004-05-27 2012-11-07 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規人工抗原提示細胞およびそれらの用途
CA2615452C (en) 2005-07-15 2015-03-31 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
JP4929174B2 (ja) * 2005-08-17 2012-05-09 タカラバイオ株式会社 リンパ球の製造方法
KR101138868B1 (ko) 2005-08-23 2012-05-14 삼성전자주식회사 생분자의 다이일렉트릭 특성을 나노입자로 향상시켜표적생분자만을 선택적으로 분리하는 ｄｅｐ 및 나노입자를이용한 표적생분자분리방법
US9388382B2 (en) 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
ES2540059T3 (es) 2006-04-26 2015-07-08 Micell Technologies, Inc. Recubrimientos que contienen múltiples fármacos
RU2009110156A (ru) * 2006-08-23 2010-09-27 Байнекс Ко., Лтд. (Kr) Способ производства активированных лимфоцитов для иммунотерапии
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CA2666789C (en) 2006-10-18 2016-11-22 Yong Zhao Embryonic-like stem cells derived from adult human peripheral blood and methods of use
AU2007315073A1 (en) * 2006-10-30 2008-05-08 Genomix Co., Ltd. Pharmaceuticals that promote functional regeneration of damaged tissues
US11426494B2 (en) * 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
US20090062237A1 (en) * 2007-06-15 2009-03-05 Mayo Foundation For Medical Education And Research Evaluating immune competence
US7816135B2 (en) * 2007-07-05 2010-10-19 Becton, Dickinson And Company Method of analyzing lymphocytes
ES2653887T3 (es) 2007-11-28 2018-02-09 Irx Therapeutics, Inc. Procedimiento para aumentar el efecto inmunológico
US20090259251A1 (en) * 2008-04-11 2009-10-15 Cohen Matthew D Loop suture
US8470562B2 (en) * 2008-04-14 2013-06-25 Irx Therapeutics, Inc. IRX-2 modified manufacturing process
CN102076350A (zh) * 2008-04-30 2011-05-25 吉诺米克斯股份有限公司 将骨髓来源的多能干细胞动员到末梢循环的药物
WO2009133940A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 損傷組織の機能的再生促進医薬
JP5676253B2 (ja) * 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
WO2010132867A1 (en) 2009-05-15 2010-11-18 Irx Therapeutics, Inc. Vaccine immunotherapy
KR20190122749A (ko) * 2009-06-11 2019-10-30 미네르바 바이오테크놀로지 코포레이션 줄기세포 및 전구세포를 배양하는 방법
WO2011044329A2 (en) 2009-10-07 2011-04-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Devices, systems and methods for cell modification
KR20120135190A (ko) 2009-10-28 2012-12-12 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 골수 간엽계 및/또는 다능성 줄기세포의 혈중 동원(動員)에 의한 조직 재생 촉진제
CN107050430B (zh) 2009-12-08 2021-10-15 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
US20150038347A1 (en) * 2010-03-19 2015-02-05 The University of Wyoming,an institution of higher of the State of Wyoming Surface enhanced raman spectroscopy
US8968362B2 (en) 2010-04-08 2015-03-03 Covidien Lp Coated looped suture
CA2799516C (en) * 2010-08-06 2016-01-05 Canine-Lab.Inc. Immunological function enhancing agent
KR20220101745A (ko) 2010-12-09 2022-07-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
EP3358011B1 (en) 2011-04-26 2020-03-04 StemRIM Inc. Peptide for inducing regeneration of tissue and use thereof
SG10201901391RA (en) 2011-05-03 2019-03-28 Immunovative Therapies Ltd Induction of il-12 using immunotherapy
DK2704741T3 (da) 2011-05-03 2017-11-27 Immunovative Therapies Ltd Fremgangsmåder til håndtering af biologiske lægemidler indeholdende levende celler
CN108593936B (zh) * 2011-06-29 2022-05-13 塞尔雷斯蒂斯有限公司 具有增强灵敏度的细胞介导免疫应答测定
WO2013036585A1 (en) * 2011-09-06 2013-03-14 The Trustees Of The University Of Pennsylvania Activation and expansion of t cell subsets using biocompatible solid substrates with tunable rigidity
JP2014526251A (ja) * 2011-09-07 2014-10-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 流体サンプルから回収された標的細胞の数を増大させる方法
SG11201400527XA (en) 2011-09-16 2014-04-28 Univ Pennsylvania Rna engineered t cells for the treatment of cancer
US9708384B2 (en) 2011-09-22 2017-07-18 The Trustees Of The University Of Pennsylvania Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
EP2773651B1 (en) 2011-11-03 2020-12-23 The Trustees of the University of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
US9783591B2 (en) 2012-02-22 2017-10-10 The Trustees Of The University Of Pennsylvania Use of the CD2 signaling domain in second-generation chimeric antigen receptors
CN104159917A (zh) 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 使用icos基cars增强抗肿瘤活性和car持久性
CA3084919A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
NZ703281A (en) 2012-05-25 2017-01-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
CN102718869B (zh) * 2012-06-06 2014-08-06 西安交通大学 一种固定化呈递免疫共刺激分子的微球及其制备方法
KR102332322B1 (ko) 2012-07-13 2021-12-01 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 형질도입된 ｔ 세포의 투여 적합성을 평가하는 방법
MX2015000426A (es) 2012-07-13 2015-07-14 Univ Pennsylvania Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico.
CN104769103B (zh) 2012-09-04 2018-06-08 塞勒克提斯公司 多链嵌合抗原受体和其用途
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
US9623078B2 (en) 2012-10-25 2017-04-18 Genomix Co., Ltd. Method for treating cardiac infarction using HMGB1 fragment
SG11201503215XA (en) 2012-10-25 2015-06-29 Genomix Co Ltd Novel method for treating spinal cord injury using hmgb1 fragment
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
PL2958943T3 (pl) 2013-02-20 2020-04-30 The Trustees Of The University Of Pennsylvania Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
CA2906514C (en) 2013-03-14 2021-07-27 Jonathan Schneck Nanoscale artificial antigen presenting cells
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
EP3623380A1 (en) 2013-03-15 2020-03-18 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP2970372B1 (en) 2013-03-15 2020-09-30 Celgene Corporation Modified t lymphocytes
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
KR102248157B1 (ko) 2013-05-13 2021-05-03 셀렉티스 Ｃｄ19 특이적 키메라 항원 수용체 및 이의 용도
CA2912375C (en) 2013-05-13 2023-03-14 Cellectis Methods for engineering highly active t cell for immunotherapy
ES2645393T3 (es) 2013-05-29 2017-12-05 Cellectis Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN107267383A (zh) 2013-12-18 2017-10-20 东洋制罐集团控股株式会社 培养容器的制造方法和固相化装置
JP6779785B2 (ja) 2013-12-19 2020-11-04 ノバルティス アーゲー ヒトメソテリンキメラ抗原受容体およびその使用
EP4420663A3 (en) 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
KR20160101073A (ko) 2013-12-20 2016-08-24 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
CN106029875A (zh) 2014-02-14 2016-10-12 塞勒克提斯公司 为了靶向存在于免疫细胞和病理细胞两者上的抗原而工程化的免疫治疗细胞
CA2942113C (en) 2014-03-11 2021-04-13 Cellectis Method for generating t-cells compatible for allogenic transplantation
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
JP6689202B2 (ja) 2014-03-19 2020-04-28 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫治療のためのｃｄ１２３特異的キメラ抗原受容体
KR102487608B1 (ko) 2014-04-07 2023-01-12 노파르티스 아게 항-cd19 키메라 항원 수용체를 사용한 암의 치료
JP2017513472A (ja) 2014-04-11 2017-06-01 セレクティスＣｅｌｌｅｃｔｉｓ アルギニンおよび／またはトリプトファン枯渇微小環境に対して抵抗性を有する免疫細胞を作製するための方法
LT3134095T (lt) * 2014-04-25 2020-06-10 Bluebird Bio, Inc. Patobulinti adaptyviųjų ląstelių gydymo priemonės gamybos būdai
RS62733B1 (sr) 2014-04-25 2022-01-31 2Seventy Bio Inc Mnd promoter himernih antigenskih receptora
EP3166968B1 (en) 2014-05-02 2021-09-22 The Trustees of the University of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
CA2947646A1 (en) 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
KR102485855B1 (ko) 2014-06-06 2023-01-09 2세븐티 바이오, 인코포레이티드 개선된 t 세포 조성물
EP3722316A1 (en) 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
KR102612313B1 (ko) 2014-07-21 2023-12-12 노파르티스 아게 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
KR102048855B1 (ko) 2014-07-29 2019-11-26 셀렉티스 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
US10544201B2 (en) 2014-07-31 2020-01-28 Cellectis ROR1 specific multi-chain chimeric antigen receptor
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
PL3183268T3 (pl) 2014-08-19 2020-09-07 Novartis Ag Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
KR102615681B1 (ko) 2014-08-28 2023-12-18 바이오아트라, 인코퍼레이티드 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
CA2959694C (en) 2014-09-04 2023-11-21 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
EP3189132B1 (en) * 2014-09-04 2020-06-24 Stemcell Technologies Inc. Soluble antibody complexes for t cell or nk cell activation and expansion
CA2961749C (en) 2014-09-17 2021-01-12 The Johns Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
CN107580628B (zh) 2014-09-17 2022-01-07 诺华股份有限公司 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
WO2016057705A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
ES2750725T3 (es) 2014-12-12 2020-03-26 Bluebird Bio Inc Receptores de antígeno quiméricos BCMA
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
WO2016109410A2 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
JP2018504143A (ja) 2015-01-26 2018-02-15 セレクティスＣｅｌｌｅｃｔｉｓ がん免疫治療のための抗ｈｓｐ７０特異的キメラ抗原受容体（ｃａｒ）
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
JP2018509148A (ja) 2015-03-11 2018-04-05 セレクティスＣｅｌｌｅｃｔｉｓ 患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法
WO2016160618A2 (en) 2015-03-27 2016-10-06 University Of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
MX2017012352A (es) 2015-04-03 2018-01-26 Eureka Therapeutics Inc Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
WO2016164580A1 (en) 2015-04-07 2016-10-13 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
SI3280729T1 (sl) 2015-04-08 2022-09-30 Novartis Ag Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
CN114149511A (zh) 2015-04-13 2022-03-08 辉瑞公司 靶向b细胞成熟抗原的嵌合抗原受体
EP3283619B1 (en) 2015-04-17 2023-04-05 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN108136021A (zh) 2015-04-25 2018-06-08 综合医院公司 用于治疗癌症的抗驱走性试剂和抗癌剂联合疗法和组合物
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
AU2016257721B2 (en) 2015-05-01 2019-11-14 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
CN114107197A (zh) * 2015-05-13 2022-03-01 泰尔茂比司特公司 细胞扩增
FI3298033T4 (fi) 2015-05-18 2023-09-22 Tcr2 Therapeutics Inc Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille
US10752670B2 (en) 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
RU2733754C2 (ru) 2015-05-20 2020-10-06 Те Брод Инститьют Инк. Общие неоантигены
IL293719B2 (en) 2015-05-21 2023-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
CN107847601A (zh) 2015-06-04 2018-03-27 南加利福尼亚大学 Lym‑1和lym‑2靶向的car细胞免疫疗法
EP3436575A1 (en) 2015-06-18 2019-02-06 The Broad Institute Inc. Novel crispr enzymes and systems
CA2995036A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
AU2016307050A1 (en) 2015-08-11 2018-02-15 Cellectis Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
ES2954480T3 (es) * 2015-08-21 2023-11-22 Mayo Found Medical Education & Res Métodos y materiales para expandir linfocitos T específicos de antígeno en cultivo
CN108136014A (zh) 2015-08-31 2018-06-08 蓝鸟生物公司 抗唾液酸tn嵌合抗原受体
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
US11890348B2 (en) 2015-09-18 2024-02-06 The General Hospital Corporation Localized delivery of anti-fugetactic agent for treatment of cancer
WO2017053889A2 (en) 2015-09-23 2017-03-30 Precision Immunotherapy, Inc. Flt3 directed car cells for immunotherapy
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
JP7316042B2 (ja) 2015-10-23 2023-07-27 ユーリカ セラピューティックス， インコーポレイテッド 抗体／ｔ細胞受容体キメラ構築物およびその使用
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
CA3003150A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
SG11201803145RA (en) 2015-11-04 2018-05-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
US11001622B2 (en) 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
US10711282B2 (en) 2015-11-23 2020-07-14 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
JP6983779B2 (ja) 2015-11-30 2021-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 非常に特異的な腫瘍細胞表面抗原を標的とするヒト抗体を用いた腫瘍特異的ペイロード送達及び免疫活性化
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
MA44140A (fr) 2015-12-22 2021-05-19 Dana Farber Cancer Inst Inc Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
CN109153975A (zh) 2015-12-28 2019-01-04 诺华股份有限公司 制备嵌合抗原受体表达细胞的方法
BR112018013074A2 (pt) 2015-12-30 2018-12-11 Novartis Ag terapias de célula efetora imune com eficácia real-çada
GB201600328D0 (en) 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
ES2942362T3 (es) 2016-01-21 2023-05-31 Pfizer Receptores quiméricos para el antígeno que se dirigen a la variante III del receptor del factor de crecimiento epidérmico
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
AU2017232616A1 (en) * 2016-03-15 2018-11-08 Nexgenia, Inc. Cell-surface molecule binding stimuli-responsive polymer compositions and methods
EP3436070A4 (en) 2016-03-29 2019-11-27 University of Southern California CHIMERIC ANTIGENIC RECEPTORS TARGETING CANCER
EP3436079B1 (en) 2016-04-01 2021-08-25 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
SI3436030T1 (sl) 2016-04-01 2023-01-31 Kite Pharma, Inc. Himerni receptorji in načini njihove uporabe
TN2018000337A1 (en) 2016-04-01 2020-01-16 Amgen Inc Chimeric receptors to flt3 and methods of use thereof
BR112018070159A2 (pt) 2016-04-01 2019-04-30 Kite Pharma, Inc. moléculas de ligação de bcma e métodos de uso das mesmas
EP3440186A4 (en) 2016-04-04 2019-12-11 Cytequest, Inc. SYSTEM, APPARATUS AND METHOD FOR THE ELECTROPORATION OF CELLS
CA3020993A1 (en) 2016-04-14 2017-10-19 Bluebird Bio, Inc. Salvage chimeric antigen receptor systems
PT3443096T (pt) 2016-04-15 2023-05-30 Novartis Ag Composições e métodos para expressão seletiva de recetores de antigénios quiméricos
CA3020599A1 (en) 2016-04-15 2017-10-19 The Children's Hospital Of Philadelphia Compositions and methods of chimeric alloantigen receptor t cells
WO2017178586A1 (en) 2016-04-15 2017-10-19 Cellectis A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
WO2017178585A1 (en) 2016-04-15 2017-10-19 Cellectis A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
WO2017192776A1 (en) * 2016-05-03 2017-11-09 The Trustees Of Columbia University In The City Of New York Method for improving expansion of t cells from patients
WO2017197234A1 (en) 2016-05-13 2017-11-16 Bioatla, Llc Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2017201488A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
CN109641012A (zh) 2016-06-07 2019-04-16 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 与bcma结合的嵌合抗原受体和car-t细胞
CN110191898B (zh) 2016-06-08 2024-05-10 英特瑞克斯顿股份有限公司 Cd33特异性嵌合抗原受体
US11466291B2 (en) 2016-07-06 2022-10-11 Cellectis Sequential gene editing in primary immune cells
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CA3030837A1 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US11242386B2 (en) 2016-07-18 2022-02-08 Helix Biopharma Corp. CEACAM6 CAR immune cells to treat cancers
CA3030748C (en) * 2016-07-21 2023-08-29 Berkeley Lights, Inc. Sorting of t lymphocytes in a microfluidic device
US20200010826A1 (en) * 2016-07-26 2020-01-09 Biomagnetic Solutions Llc Simultaneous separation and activation of t cells from blood products with subsequent stimulation to expand t cells
AU2017302668B9 (en) 2016-07-28 2023-06-22 Novartis Ag Combination therapies of chimeric antigen receptors and PD-1 inhibitors
CN110267677A (zh) 2016-08-01 2019-09-20 诺华股份有限公司 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US11630103B2 (en) 2016-08-17 2023-04-18 The Broad Institute, Inc. Product and methods useful for modulating and evaluating immune responses
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
EP3957997A1 (en) 2016-08-26 2022-02-23 Juno Therapeutics, Inc. Methods of enumerating particles present in a cell composition
CN110121352B (zh) 2016-09-01 2020-12-11 嵌合体生物工程公司 Gold优化的car t-细胞
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
US20200166518A1 (en) * 2016-09-12 2020-05-28 IsoPlexis Corporation System and methods for multiplexed analysis of cellular and other immunotherapeutics
BR112019004711A2 (pt) 2016-09-14 2019-05-28 Janssen Biotech Inc receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
CA3037518A1 (en) 2016-09-21 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
AU2017341047B2 (en) 2016-10-07 2024-10-10 Novartis Ag Chimeric antigen receptors for the treatment of cancer
US20200016202A1 (en) 2016-10-07 2020-01-16 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
AU2017341048A1 (en) 2016-10-07 2019-05-23 TCR2 Therapeutics Inc. Compositions and methods for T-cell receptors reprogramming using fusion proteins
WO2018073391A1 (en) 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
WO2018073394A1 (en) 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
CN110381961A (zh) * 2016-10-24 2019-10-25 Gpb科学有限责任公司 用于治疗用途的细胞和组合物的制备中的确定性侧向位移
MA46723A (fr) 2016-11-04 2019-09-11 Bluebird Bio Inc Compositions de lymphocytes t car anti-bcma
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
CN110072885B (zh) 2016-11-17 2023-12-19 2赛文缇生物公司 TGFβ信号转换器
EP3544996A2 (en) 2016-11-22 2019-10-02 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
MX2019006045A (es) 2016-11-23 2019-11-11 Harpoon Therapeutics Inc Proteinas triespecificas dirigidas a psma y metodos de uso.
AU2017363300A1 (en) 2016-11-23 2019-06-20 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
WO2018115189A1 (en) 2016-12-21 2018-06-28 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
CN110234343A (zh) 2016-12-21 2019-09-13 T细胞受体治疗公司 用于治疗癌症的经工程改造t细胞
EP3346001A1 (en) 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
WO2018127585A1 (en) 2017-01-06 2018-07-12 Txcell Monospecific regulatory t cell population with cytotoxicity for b cells
IL267865B2 (en) 2017-01-10 2024-07-01 Intrexon Corp Modulation of expression of polypeptides through a new system for changing gene expression
TW201831517A (zh) 2017-01-12 2018-09-01 美商優瑞科生物技術公司 靶向組織蛋白h3肽/mhc複合體之構築體及其用途
GB201700553D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
EP3556378A4 (en) 2017-01-27 2020-11-18 StemRIM Inc. THERAPEUTIC AGENT FOR CARDIOMYOPATHY, OLD MYOCARDINAL INFARM AND CHRONIC HEART FAILURE
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018148180A2 (en) 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
CA3053006C (en) 2017-02-08 2023-09-05 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
TWI785009B (zh) 2017-02-14 2022-12-01 美商凱特製藥公司 Ｃｄ７０結合分子及使用彼之方法
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
TW201837175A (zh) 2017-03-13 2018-10-16 美商凱特製藥公司 用於黑色素瘤之嵌合抗原受體及其用途
CN110678197A (zh) 2017-03-15 2020-01-10 牛津生物医学（英国）有限公司 方法
US11547694B2 (en) 2017-03-23 2023-01-10 The General Hospital Corporation CXCR4/CXCR7 blockade and treatment of human papilloma virus-associated disease
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US11690873B2 (en) 2017-03-31 2023-07-04 Cellectis Sa Universal chimeric antigen receptor T cells specific for CD22
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
CA3057880A1 (en) 2017-04-03 2018-10-11 Kite Pharma, Inc. Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
WO2018189360A1 (en) 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
EP3612275A1 (en) 2017-04-19 2020-02-26 Allogene Therapeutics, Inc. Improved t cell compositions and methods
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
CN110741016A (zh) 2017-04-26 2020-01-31 优瑞科生物技术公司 嵌合抗体/t-细胞受体构筑体及其用途
SG11201909728XA (en) 2017-04-26 2019-11-28 Eureka Therapeutics Inc Constructs specifically recognizing glypican 3 and uses thereof
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN110913908B (zh) 2017-05-12 2022-05-27 哈普恩治疗公司 靶向msln的三特异性蛋白质及使用方法
CN113896792A (zh) 2017-05-12 2022-01-07 哈普恩治疗公司 间皮素结合蛋白质
WO2018206791A1 (en) 2017-05-12 2018-11-15 Cellectis Protease based switch chimeric antigen receptors for safer cell immunotherapy
US20200368278A1 (en) 2017-05-18 2020-11-26 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
EP3630950A1 (en) 2017-05-26 2020-04-08 Kite Pharma, Inc. Methods of making and using embryonic mesenchymal progenitor cells
MX2019013923A (es) 2017-06-02 2020-01-21 Pfizer Receptores de antigenos quimericos que se dirigen a flt3.
US11118168B2 (en) 2017-06-07 2021-09-14 Precigen, Inc. Expression of novel cell tags
WO2018232020A1 (en) 2017-06-13 2018-12-20 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3638218A4 (en) 2017-06-14 2021-06-09 The Broad Institute, Inc. COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
CA3066774A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
MA49512A (fr) 2017-06-28 2020-05-06 Regeneron Pharma Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
WO2019002633A1 (en) 2017-06-30 2019-01-03 Cellectis CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
WO2019018402A2 (en) 2017-07-17 2019-01-24 Janssen Biotech, Inc. ANTIGEN-BINDING REGIONS DIRECTED AGAINST FIBRONECTIN TYPE III DOMAINS AND METHODS OF USING THE SAME
SG11202000425QA (en) * 2017-07-21 2020-02-27 Berkeley Lights Inc Antigen-presenting synthetic surfaces, covalently functionalized surfaces, activated t cells, and uses thereof
WO2019016360A1 (en) 2017-07-21 2019-01-24 Cellectis MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
WO2019038368A1 (en) 2017-08-23 2019-02-28 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft CHIMERIC ANTIGEN RECEPTOR AND CAR CXCR5 BINDING T CARRIER
US12076369B2 (en) 2017-09-01 2024-09-03 The Frances Crick Institute Limited Immunoregulatory molecules and uses therefor
CN111448215B (zh) 2017-09-19 2024-01-16 英属哥伦比亚大学 抗-hla-a2抗体及其使用方法
US11814432B2 (en) 2017-09-20 2023-11-14 The University Of British Columbia Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof
KR20200066616A (ko) 2017-09-21 2020-06-10 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
AU2018346719A1 (en) 2017-10-06 2020-04-23 Oslo Universitetssykehus Hf Chimeric antigen receptors
WO2019072824A1 (en) 2017-10-09 2019-04-18 Cellectis IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
EP3694871A4 (en) 2017-10-13 2021-11-10 Harpoon Therapeutics, Inc. B-CELL MATURATION ANTIG-BINDING PROTEINS
BR112020007196A2 (pt) 2017-10-13 2020-12-01 Harpoon Therapeutics, Inc. proteínas triespecíficas e métodos de uso
AR113777A1 (es) 2017-10-18 2020-06-10 Kite Pharma Inc Métodos de administración de una inmunoterapia con receptores de antígenos quiméricos
CA3084476A1 (en) 2017-10-19 2019-04-25 Cellectis Targeted gene integration of nk inhibitors genes for improved immune cells therapy
MX2020004229A (es) 2017-10-25 2020-07-22 Novartis Ag Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
CA3079096A1 (en) 2017-11-01 2019-05-09 Allogene Therapeutics, Inc. Modified caspase-9 polypeptides and methods of use thereof
WO2019086711A1 (en) 2017-11-06 2019-05-09 Ludwig Institute For Cancer Research Ltd Method for expansion of lymphocytes
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
CN111787938A (zh) 2017-11-15 2020-10-16 诺华股份有限公司 靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
TW201925782A (zh) 2017-11-30 2019-07-01 瑞士商諾華公司 靶向bcma之嵌合抗原受體及其用途
EP3718561A4 (en) 2017-12-01 2021-07-21 Stemrim Inc. Therapy for inflammatory bowel disease
WO2019118883A1 (en) * 2017-12-15 2019-06-20 Northwestern University Structure-function relationships in the development of immunotherapeutic agents
WO2019126146A1 (en) 2017-12-19 2019-06-27 Xcell Biosciences, Inc. Methods of modulating cell phenotype by way of regulating the gaseous environment
TWI699218B (zh) 2017-12-22 2020-07-21 財團法人工業技術研究院 體外活化及/或擴增免疫細胞的方法
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
TW201930591A (zh) 2018-01-08 2019-08-01 瑞士商諾華公司 用於與嵌合抗原受體療法併用之免疫增強rna
PL3737765T3 (pl) 2018-01-12 2022-04-11 Curocell Inc. Komórki układu odpornościowego wzmocnione z użyciem podwójnego shrna i kompozycja zawierająca te komórki
CA3087481A1 (en) 2018-01-15 2019-07-18 Pfizer Inc. Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist
EP3765054A4 (en) 2018-01-19 2022-01-12 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR TARGETING GAMMA DELTA T CELLS WITH CHIMERIC ANTIGEN RECEPTORS
EP3694546A1 (en) 2018-01-30 2020-08-19 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
EP3746135A4 (en) 2018-01-30 2022-03-09 Foghorn Therapeutics Inc. METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019152742A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Chimeric antigen receptors targeting cd70
WO2019152705A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Antibodies specific for cd70 and their uses
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
CA3090793A1 (en) 2018-02-16 2019-08-22 Kite Pharma, Inc. Modified pluripotent stem cells and methods of making and use
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
MA52114A (fr) 2018-02-28 2021-01-06 Juno Therapeutics Inc Procédés de détection de particules présentes dans une composition cellulaire
WO2019169290A1 (en) 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
JP7037218B2 (ja) 2018-03-14 2022-03-16 サーフィス オンコロジー インコーポレイテッド Ｃｄ３９と結合する抗体及びその使用
BR112020018620A2 (pt) 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. Composições de regulação gênica e métodos para imunoterapia aprimorada
BR112020018658A2 (pt) 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. Composições de regulação gênica e métodos para imu-noterapia aprimorada
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
WO2019183455A1 (en) 2018-03-22 2019-09-26 Windmil Therapeutics, Inc. Prostate cancer specific marrow infiltrating lymphocytes and uses thereof
MA52203A (fr) 2018-04-10 2021-02-17 Amgen Inc Récepteurs chimères pour dll3 et leurs procédés d'utilisation
TWI784324B (zh) 2018-04-12 2022-11-21 美商凱特製藥公司 利用腫瘤微環境之特性之嵌合受體t細胞治療
SG11202010116PA (en) 2018-04-13 2020-11-27 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
SG11202009626QA (en) 2018-04-20 2020-10-29 Medizinische Hochschule Hannover Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210115378A1 (en) * 2018-05-09 2021-04-22 Yale University Compositions and systems for ex vivo cell modulation and methods of use thereof
WO2019217913A1 (en) 2018-05-10 2019-11-14 Sensei Biotherapeutics, Inc. Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
KR20210008502A (ko) 2018-05-11 2021-01-22 크리스퍼 테라퓨틱스 아게 암을 치료하기 위한 방법 및 조성물
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US11905321B2 (en) 2018-06-05 2024-02-20 The Trustees Of The University Of Pennsylvania Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells
KR20210020932A (ko) 2018-06-13 2021-02-24 노파르티스 아게 Bcma 키메라 항원 수용체 및 이의 용도
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
EP3806903B1 (en) 2018-06-14 2024-02-14 2seventy bio, Inc. Cd79a chimeric antigen receptors
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
EP3806904A4 (en) 2018-06-18 2022-04-27 Eureka Therapeutics, Inc. PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED CONSTRUCTS AND USES THEREOF
CN112533629A (zh) 2018-06-19 2021-03-19 阿尔莫生物科技股份有限公司 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
US20210155941A1 (en) 2018-06-22 2021-05-27 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
WO2020007593A1 (en) 2018-07-02 2020-01-09 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
US20210330788A1 (en) 2018-07-11 2021-10-28 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
EP3823993A1 (en) 2018-07-18 2021-05-26 Amgen Inc. Chimeric receptors to steap1 and methods of use thereof
SI3823665T1 (sl) 2018-07-19 2024-03-29 Regeneron Pharmaceuticals, Inc. Himerni antigenski receptorji s specifičnostjo BCMA in njihove uporabe
JP2021531813A (ja) 2018-08-02 2021-11-25 カイト ファーマ インコーポレイテッドKite Pharma, Inc キメラ抗原受容体療法のｔ細胞の増殖動態及びその使用
BR112021002579A2 (pt) 2018-08-10 2021-05-11 Sangamo Therapeutics France novas construções de car compreendendo os domínios de tnfr2
KR102543325B1 (ko) 2018-08-13 2023-06-13 루트패스 제노믹스, 인크. 쌍을 이룬 이분 면역수용체 폴리뉴클레오티드의 고처리량 클로닝 및 이의 적용
US20210177832A1 (en) 2018-08-20 2021-06-17 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
WO2020041384A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
CN113039209A (zh) 2018-08-30 2021-06-25 T细胞受体治疗公司 用于使用融合蛋白进行tcr重编程的组合物和方法
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
CA3109959A1 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
CA3110905A1 (en) 2018-08-31 2020-03-05 Invectys SA Chimeric antigen receptors against multiple hla-g isoforms
AU2019337759A1 (en) 2018-09-10 2021-03-11 Legend Biotech Ireland Limited Single-domain antibodies against CD33 and constructs thereof
US11993766B2 (en) 2018-09-21 2024-05-28 Bruker Cellular Analysis, Inc. Functionalized well plate, methods of preparation and use thereof
KR20210086623A (ko) 2018-09-25 2021-07-08 하푼 테라퓨틱스, 인크. Ddl3 결합 단백질 및 사용 방법
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
WO2020069409A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
WO2020086647A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof
JP2022509017A (ja) 2018-11-07 2022-01-20 クリスパー セラピューティクス アクチェンゲゼルシャフト 抗ｐｔｋ７免疫細胞癌療法
KR20210089712A (ko) 2018-11-07 2021-07-16 크리스퍼 테라퓨틱스 아게 항-cd33 면역세포 암 치료법
MX2021005395A (es) 2018-11-07 2021-09-14 Crispr Therapeutics Ag Terapia del cáncer con células inmunitarias anti-liv1.
BR112021008963A2 (pt) 2018-11-08 2021-09-14 Neximmune, Inc. Composições de célula t com propriedades fenotípicas melhoradas
EP3880307A1 (en) 2018-11-14 2021-09-22 Fundación Pública Andaluza Progreso Y Salud Polynucleotide for safer and more effective immunotherapies
EP3887507A1 (en) 2018-11-30 2021-10-06 Janssen Biotech, Inc. Gamma delta t cells and uses thereof
AU2019398101A1 (en) 2018-12-10 2021-06-10 Amgen Inc. Mutated piggybac transposase
US11793834B2 (en) 2018-12-12 2023-10-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
GB201900858D0 (en) 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
US20230066136A1 (en) 2019-01-29 2023-03-02 Foghorn Therapeutics Inc. Compounds and uses thereof
BR112021016046A2 (pt) 2019-02-15 2021-11-09 Editas Medicine Inc Células assassinas naturais modificadas (nk) para imunoterapia
US20220088075A1 (en) 2019-02-22 2022-03-24 The Trustees Of The University Of Pennsylvania Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
CA3130080A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
MX2021010441A (es) 2019-03-01 2021-09-21 Allogene Therapeutics Inc Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
JP2022522778A (ja) 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロシクリル化合物及びその使用
WO2020182681A1 (en) 2019-03-08 2020-09-17 Klinikum Der Universität München Ccr8 expressing lymphocytes for targeted tumor therapy
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
CN113631575A (zh) 2019-03-15 2021-11-09 笛卡尔疗法股份有限公司 抗bcma嵌合抗原受体
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
JP2022526340A (ja) 2019-03-25 2022-05-24 マックス－デルブリュック－ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ－ゲマインシャフト Ｅｂａｇ９を阻害することによる細胞溶解性ｔ細胞の活性の増強
EP3947471A4 (en) 2019-03-27 2023-03-15 The Trustees of The University of Pennsylvania TN-MUC1 CHIMERIC ANTIGEN RECEPTOR (CAR) T-LYMPHOCYTE THERAPY
AU2020253491A1 (en) 2019-04-05 2021-10-28 Rootpath Genomics, Inc. Compositions and methods for T-cell receptor gene assembly
WO2020206061A1 (en) 2019-04-05 2020-10-08 Bluebird Bio, Inc. Manufacturing anti-bcma car t cells
WO2020213724A1 (ja) 2019-04-19 2020-10-22 中外製薬株式会社 抗体改変部位認識キメラ受容体
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
CA3132509A1 (en) 2019-04-26 2020-10-29 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car t cells
FI3959235T3 (fi) 2019-04-26 2023-09-27 Allogene Therapeutics Inc Rituksimabiresistenttejä kimeerisiä antigeenireseptoreja ja niiden käyttö
SG11202112123RA (en) 2019-05-03 2021-11-29 Kite Pharma Inc Methods of administering chimeric antigen receptor immunotherapy
US20230086537A1 (en) 2019-05-07 2023-03-23 Modernatx, Inc. Differentially expressed immune cell micrornas for regulation of protein expression
CA3140430A1 (en) 2019-05-14 2020-11-19 Harpoon Therapeutics, Inc. Epcam binding proteins and methods of use
WO2020232437A1 (en) * 2019-05-16 2020-11-19 CyteQuest, Inc. Devices, methods, and systems for electroporation
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
JP2022537658A (ja) 2019-06-05 2022-08-29 ドイチェス ツェントラム フューア ノイロデジェネラティヴ エアクランクンゲン エー． ファウ．（ディーゼットエヌイー） 神経学的自己免疫疾患における中枢神経系を標的とする自己抗体に結合するキメラ自己抗体受容体（ｃａａｒ）
BR112021026382A2 (pt) 2019-06-27 2022-02-08 Crispr Therapeutics Ag Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer
CN114341187A (zh) 2019-07-12 2022-04-12 中外制药株式会社 抗突变型fgfr3抗体及其用途
CN110387058A (zh) * 2019-07-24 2019-10-29 南通大学 一种促进细胞在水凝胶上面正常生长的方法
BR112022001194A2 (pt) 2019-07-24 2022-06-07 Regeneron Pharma Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
WO2021030182A1 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Bifunctional single variable domain t cell receptors and uses thereof
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
US20220305056A1 (en) 2019-08-27 2022-09-29 Janssen Biotech, Inc. Chimeric antigen receptor system and uses thereof
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
EP4025689A1 (en) 2019-09-06 2022-07-13 CRISPR Therapeutics AG Genetically engineered t cells having improved persistence in culture
CN114729384A (zh) 2019-09-12 2022-07-08 博德研究所 工程化腺相关病毒衣壳
WO2021055329A1 (en) 2019-09-16 2021-03-25 Surface Oncology, Inc. Anti-cd39 antibody compositions and methods
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
EP4034561A2 (en) 2019-09-27 2022-08-03 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
EP3808766A1 (en) 2019-10-15 2021-04-21 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
TW202132314A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
EP4054719A1 (en) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras inhibitors
JP2022553857A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
WO2021091978A1 (en) 2019-11-05 2021-05-14 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
AU2020380315A1 (en) 2019-11-08 2022-05-26 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
EP4055384A2 (en) 2019-11-08 2022-09-14 Kiyatec, Inc. Methods of screening to determine effective dosing of cancer therapeutics
WO2021096868A1 (en) 2019-11-12 2021-05-20 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
TW202134264A (zh) 2019-11-26 2021-09-16 瑞士商諾華公司 嵌合抗原受體及其用途
WO2021108613A1 (en) 2019-11-26 2021-06-03 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
MX2022006962A (es) 2019-12-11 2022-09-12 A2 Biotherapeutics Inc Receptor quimerico de antigenos basado en el miembro 1 de la subfamilia b de receptores similares a inmunoglobulina de leucocitos (lilrb1).
MX2022007833A (es) 2019-12-23 2022-09-23 Cellectis Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos.
CN113025570A (zh) * 2019-12-24 2021-06-25 华东数字医学工程研究院 一种t细胞增殖方法及其用途
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
MX2022008305A (es) 2020-01-07 2022-08-08 Revolution Medicines Inc Dosificacion de inhibidores de shp2 y metodos de tratamiento del cancer.
US20230076768A1 (en) 2020-01-14 2023-03-09 Synthekine, Inc. IL2 Orthologs and Methods of Use
CN115348868A (zh) 2020-01-17 2022-11-15 克里斯珀医疗股份公司 表达bcma特异性嵌合抗原受体的基因工程化t细胞及其在癌症疗法中的用途
CN115427436A (zh) 2020-01-24 2022-12-02 里珍纳龙药品有限公司 黑素瘤优先表达抗原（prame）t细胞受体及其使用方法
EP4096651A4 (en) 2020-01-29 2024-01-24 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
CN113244029A (zh) * 2020-02-07 2021-08-13 脉胜医疗技术公司 具有可生物降解层的支架
US20230111593A1 (en) 2020-02-14 2023-04-13 Novartis Ag Method of predicting response to chimeric antigen receptor therapy
EP4106806A4 (en) 2020-02-21 2024-07-24 Harpoon Therapeutics Inc FLT3 BINDING PROTEINS AND METHODS OF USE
EP4110377A2 (en) 2020-02-27 2023-01-04 Novartis AG Methods of making chimeric antigen receptor-expressing cells
AU2021232141A1 (en) 2020-03-03 2022-09-22 Janssen Biotech, Inc. ꝩδ T cells and uses thereof
EP4114449A2 (en) 2020-03-05 2023-01-11 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
EP4114860A1 (en) 2020-03-06 2023-01-11 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
MX2022011683A (es) 2020-03-20 2022-12-08 Inst Nat Sante Rech Med Receptor de antigeno quimerico especifico para cd45rc humano y usos del mismo.
CN115916963A (zh) 2020-03-27 2023-04-04 门德斯有限公司 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
IL297236A (en) 2020-04-17 2022-12-01 Hope City Cells modified with a flt3-specific chimeric antigen receptor for the treatment of flt3-positive cancers
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
CN115485303A (zh) 2020-05-05 2022-12-16 瑞泽恩制药公司 包含CD28ζ和CD3ζ的CAR
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
WO2021252635A1 (en) 2020-06-11 2021-12-16 A2 Biotherapeutics, Inc. Compositions and methods for treating cancers
MX2022016355A (es) 2020-06-18 2023-04-03 Revolution Medicines Inc Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
CA3189677A1 (en) 2020-07-17 2022-01-20 Instil Bio (Uk) Limited Chimeric molecules providing targeted costimulation for adoptive cell therapy
WO2022016112A1 (en) 2020-07-17 2022-01-20 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
KR20230040331A (ko) 2020-07-21 2023-03-22 알로젠 테라퓨틱스 인코포레이티드 강화된 신호 전달 및 활성을 갖는 키메라 항원 수용체 및 이의 용도
EP4185616A1 (en) 2020-07-24 2023-05-31 Cellectis S.A. T-cells expressing immune cell engagers in allogenic settings
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
EP4192874A1 (en) 2020-08-05 2023-06-14 Dragonfly Therapeutics, Inc. Antibodies targeting egfr and use thereof
WO2022036068A1 (en) 2020-08-13 2022-02-17 A2 Biotherapeutics, Inc. Gene fusions for control of genetically modified cells
WO2022036041A1 (en) 2020-08-14 2022-02-17 Kite Pharma, Inc Improving immune cell function
JP2023538114A (ja) 2020-08-20 2023-09-06 エー２ バイオセラピューティクス， インコーポレイテッド メソテリン陽性がんを治療するための組成物及び方法
JP2023538115A (ja) 2020-08-20 2023-09-06 エー２ バイオセラピューティクス， インコーポレイテッド Ｃｅａｃａｍ陽性がんを治療するための組成物及び方法
HRP20240903T1 (hr) 2020-08-20 2024-10-11 A2 Biotherapeutics, Inc. Pripravci i metode za liječenje egfr pozitivnih karcinoma
WO2022043312A1 (en) 2020-08-24 2022-03-03 Charité - Universitätsmedizin Berlin Chimeric antigen receptor (car)-expressing cells recognizing cea
EP4199959A1 (en) 2020-08-24 2023-06-28 Charité - Universitätsmedizin Berlin A chimeric antigen receptor construct encoding a checkpoint inhibitory molecule and an immune stimulatory cytokine and car-expressing cells recognizing cd44v6
CN116457358A (zh) 2020-09-15 2023-07-18 锐新医药公司 作为ras抑制剂以治疗癌症的吲哚衍生物
US11976297B2 (en) 2020-09-21 2024-05-07 A2 Biotherapeutics, Inc. Engineered immune cells with receptor cross-talk
EP4215609A1 (en) 2020-09-21 2023-07-26 Fundación Pública Andaluza Progreso Y Salud Polynucleotide for physiological expression in t-cells
KR20230074515A (ko) 2020-09-23 2023-05-30 크리스퍼 테라퓨틱스 아게 개선된 기능성 및 지속성을 갖는 붕괴된 레그나제-1 및/또는 tgfbrii를 지니는 유전자 조작된 t 세포
US20230398149A1 (en) 2020-11-04 2023-12-14 Celgene Corporation Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
US20220168407A1 (en) 2020-11-05 2022-06-02 Dcprime B.V. Use of tumor-independent antigens in immunotherapies
EP4243857A1 (en) 2020-11-13 2023-09-20 Novartis AG Combination therapies with chimeric antigen receptor (car)-expressing cells
WO2022115492A1 (en) 2020-11-24 2022-06-02 Lyell Immunopharma, Inc. Methods for making, compositions comprising, and methods of using rejuvenated t cells
JP2023552773A (ja) 2020-12-04 2023-12-19 セルジーン コーポレーション 炎症関連可溶性因子の阻害剤と組み合わせたキメラ抗原受容体（ｃａｒ）ｔ細胞療法の使用
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
AU2021409801A1 (en) 2020-12-21 2023-06-22 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
EP4019538A1 (en) 2020-12-22 2022-06-29 Charité - Universitätsmedizin Berlin Reprogramming immune cells by targeted integration of zeta-deficient chimeric antigen receptor transgenes
US20240041927A1 (en) 2020-12-22 2024-02-08 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Chimeric autoantibody receptor (caar) comprising a nicotinic acetylcholine receptor autoantigen
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
EP4267604A1 (en) 2020-12-23 2023-11-01 Gadeta B.V. Chimeric, transmembrane proteins with bidirectional signalling activity
WO2022137181A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
US20220202859A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
US20220221463A1 (en) 2021-01-10 2022-07-14 Kite Pharma, Inc. T cell therapy
TW202239768A (zh) 2021-01-27 2022-10-16 美商萊爾免疫藥物股份有限公司 改良之免疫細胞療法
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
MX2023008662A (es) 2021-01-28 2023-08-01 Allogene Therapeutics Inc Metodos para transducir celulas inmunitarias.
MX2023008809A (es) 2021-01-29 2023-08-04 Allogene Therapeutics Inc ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
EP4294828A1 (en) 2021-02-16 2023-12-27 A2 Biotherapeutics, Inc. Compositions and methods for treating her2 positive cancers
CA3211006A1 (en) 2021-02-20 2022-08-25 Kite Pharma, Inc. Gene markers for sellecting immunotherapies
US20220281950A1 (en) 2021-03-04 2022-09-08 Allogene Therapeutics, Inc. Fasl expression and fasr gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death
JP2024512324A (ja) 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
WO2022189967A1 (en) 2021-03-09 2022-09-15 Crispr Therapeutics Ag Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
IL305571A (en) 2021-03-11 2023-10-01 Kite Pharma Inc Improving the function of immune system cells
CA3216358A1 (en) 2021-04-08 2022-10-13 Janssen Biotech, Inc. Materials and methods for enhanced stem-cell like memory t cell engineering
JP2024517413A (ja) 2021-04-16 2024-04-22 セルジーン コーポレーション 以前に幹細胞移植を受けた患者におけるｔ細胞療法
MX2023012760A (es) 2021-04-30 2023-11-13 Cellectis Sa Nuevos cars anti-muc1 y celulas inmunitarias editadas geneticamente para inmunoterapia contra el cancer de tumores solidos.
CA3217914A1 (en) 2021-05-04 2022-11-10 Kevin BRAY Chimeric antigen receptors with mage-a4 specificity and uses thereof
KR20240017811A (ko) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
AU2022270116A1 (en) 2021-05-05 2023-12-21 Revolution Medicines, Inc. Ras inhibitors
US20240207319A1 (en) 2021-05-06 2024-06-27 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
TW202309077A (zh) 2021-05-12 2023-03-01 瑞士商Ｃｒｉｓｐｒ治療公司 用於治療實性瘤的靶向ｃｄ７０的基因工程化免疫細胞
WO2022238962A1 (en) 2021-05-12 2022-11-17 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
WO2022241151A2 (en) 2021-05-14 2022-11-17 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
WO2022243529A1 (en) 2021-05-20 2022-11-24 Cellectis S.A. GENE THERAPY FOR THE TREATMENT OF HYPER-IgE SYNDROME (HIES) BY TARGETED GENE INTEGRATION
EP4341300A1 (en) 2021-05-21 2024-03-27 Cellectis S.A. Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
US20240277842A1 (en) 2021-06-07 2024-08-22 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2022266203A1 (en) 2021-06-15 2022-12-22 Allogene Therapeutics, Inc. Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence
US11945876B2 (en) 2021-06-16 2024-04-02 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023288278A1 (en) 2021-07-16 2023-01-19 Instil Bio (Uk) Limited Chimeric molecules providing targeted costimulation for adoptive cell therapy
WO2023007373A1 (en) 2021-07-26 2023-02-02 Crispr Therapeutics Ag Methods for manufacturing genetically engineered car-t cells
IL310550A (en) 2021-08-04 2024-03-01 Univ Colorado Regents LAT-activating chimeric antigen receptor T cells and methods of using them
AU2022324456A1 (en) 2021-08-05 2024-02-15 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
US20240342282A1 (en) 2021-08-13 2024-10-17 Ludwig-Maximilians-Universität München Anti-csf1r car expressing lymphocytes for targeted tumor therapy
EP4387991A1 (en) 2021-08-18 2024-06-26 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
CA3228536A1 (en) 2021-08-24 2023-03-02 Yugang Guo Il-10 expressing cells for enhanced cancer immunotherapies
KR20240101546A (ko) 2021-09-03 2024-07-02 고 테라퓨틱스, 인크. 항-글리코-lamp1 항체 및 그의 용도
JP2024536722A (ja) 2021-09-03 2024-10-08 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｍｅｔ抗体およびその使用
US20230128917A1 (en) 2021-09-14 2023-04-27 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023081813A1 (en) 2021-11-05 2023-05-11 St. Jude Children's Research Hospital, Inc. Zip cytokine receptors
WO2023081894A2 (en) 2021-11-08 2023-05-11 St. Jude Children's Research Hospital, Inc. Pre-effector car-t cell gene signatures
WO2023084399A1 (en) 2021-11-09 2023-05-19 Crispr Therapeutics Ag Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7
WO2023091954A2 (en) 2021-11-19 2023-05-25 The Trustees Of The University Of Pennsylvania Engineered pan-leukocyte antigen cd45 to facilitate car t cell therapy
WO2023092119A2 (en) 2021-11-22 2023-05-25 Ludwig Institute For Cancer Research Ltd Methods for predicting responsiveness to a cancer therapy
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
US20230346836A1 (en) 2021-12-22 2023-11-02 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
WO2023150181A1 (en) 2022-02-01 2023-08-10 President And Fellows Of Harvard College Methods and compositions for treating cancer
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
US20230296610A1 (en) 2022-02-15 2023-09-21 Kite Pharma, Inc. Predicting adverse events from immunotherapy
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
AU2023230110A1 (en) 2022-03-08 2024-10-24 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
US20230303713A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
US20230331841A1 (en) 2022-03-23 2023-10-19 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
AU2023244350A1 (en) 2022-03-29 2024-09-05 Allogene Therapeutics Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
WO2023196933A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Chimeric antigen receptor t cells and methods of use thereof
WO2023196921A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Granzyme expressing t cells and methods of use
IL316032A (en) 2022-04-08 2024-11-01 Regeneron Pharmaceuticals Inc Multicomponent receptor and signaling complexes
EP4276174A1 (en) 2022-05-09 2023-11-15 Cellectis S.A. Gene therapy for the treatment of activated pi3kinase delta syndrome type 1 (apds1)
WO2023220644A1 (en) 2022-05-10 2023-11-16 Yale University Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230512A1 (en) 2022-05-26 2023-11-30 2Seventy Bio, Inc. Compositions for maintaining lentiviral vector and uses thereof
WO2023240182A1 (en) 2022-06-08 2023-12-14 St. Jude Children's Research Hospital, Inc. Disruption of kdm4a in t cells to enhance immunotherapy
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2023242434A1 (en) 2022-06-17 2023-12-21 Gadeta B.V. Modified immune cells
WO2023248110A1 (en) 2022-06-20 2023-12-28 Crispr Therapeutics Ag Base editing proteins and uses thereof
WO2024003786A1 (en) 2022-06-29 2024-01-04 Crispr Therapeutics Ag Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
WO2024003334A1 (en) 2022-06-30 2024-01-04 Cellectis S.A. Enhancing safety of t-cell-mediated immunotherapy
TW202408487A (zh) 2022-07-06 2024-03-01 美商維維迪昂醫療公司 包含ｗｒｎ解旋酶抑制劑之醫藥組成物
US20240067612A1 (en) 2022-07-06 2024-02-29 Vividion Therapeutics, Inc. Pharmaceutical compositions comprising wrn helicase inhibitors
WO2024020429A1 (en) 2022-07-22 2024-01-25 Lyell Immunopharma, Inc. Immune cell therapy
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2024030441A1 (en) 2022-08-02 2024-02-08 National University Corporation Hokkaido University Methods of improving cellular therapy with organelle complexes
US20240091261A1 (en) 2022-08-26 2024-03-21 Kite Pharma, Inc. Immune cell function
WO2024056809A1 (en) 2022-09-15 2024-03-21 Novartis Ag Treatment of autoimmune disorders using chimeric antigen receptor therapy
WO2024059787A1 (en) 2022-09-16 2024-03-21 St. Jude Children's Research Hospital, Inc. Disruption of asxl1 in t cells to enhance immunotherapy
WO2024062388A2 (en) 2022-09-20 2024-03-28 Crispr Therapeutics Ag Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
EP4353253A1 (en) 2022-10-10 2024-04-17 Charité - Universitätsmedizin Berlin Purification of tcr-modified t cells using tcr-specific car-nk cells
EP4353252A1 (en) 2022-10-10 2024-04-17 Charité - Universitätsmedizin Berlin Antigen-specific t cells by gene editing of cd3 epsilon
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies
WO2024092092A2 (en) 2022-10-27 2024-05-02 Cargo Therapeutics, Inc. Compositions and methods for allogeneic immunotherapies
WO2024091669A1 (en) 2022-10-28 2024-05-02 Ginkgo Bioworks, Inc. Chimeric antigen receptors comprising an intracellular domain pair
WO2024092227A1 (en) 2022-10-28 2024-05-02 Kite Pharma, Inc. Factors for optimizing immunotherapy
WO2024092152A1 (en) 2022-10-28 2024-05-02 Kite Pharma, Inc. Improving efficacy and durable response of immunotherapy
WO2024097642A1 (en) 2022-10-31 2024-05-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine
WO2024094775A1 (en) 2022-11-03 2024-05-10 Cellectis S.A. Enhancing efficacy and safety of t-cell-mediated immunotherapy
US20240216430A1 (en) 2022-11-28 2024-07-04 Allogene Therapeutics, Inc. Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
WO2024119074A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Stealth lipid nanoparticle compositions for cell targeting
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024155821A1 (en) 2023-01-18 2024-07-25 Yale University Chimeric antigen receptors (car) with intrinsically disordered regions and methods of use thereof
WO2024160845A1 (en) 2023-01-30 2024-08-08 Ludwig-Maximilians-Universität München Anti-cd86 car expressing lymphocytes for targeted tumor therapy
WO2024175657A1 (en) 2023-02-22 2024-08-29 Astrazeneca Ab Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma)
WO2024182539A1 (en) 2023-02-28 2024-09-06 Lyell Immunopharma, Inc. Methods of culturing reprogrammed cells
WO2024192108A1 (en) 2023-03-14 2024-09-19 Evolveimmune Therapeutics, Inc. Genetically modified car t cells and methods of making and using the same
WO2024196689A1 (en) 2023-03-17 2024-09-26 Kite Pharma, Inc. Impact of tumor microenvironment on efficacy of immunotherapy
WO2024194471A1 (en) 2023-03-23 2024-09-26 Alentis Therapeutics Ag Biomarker for cancer treatment using anti-claudin-1 antibodies
WO2024206155A1 (en) 2023-03-24 2024-10-03 Cornell University Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211478A1 (en) 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a lymphotoxin beta receptor agonist
US20240352036A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
US20240352038A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024218318A1 (en) 2023-04-21 2024-10-24 Charité - Universitätsmedizin Berlin Markers for predicting therapeutic efficacy of a t cell

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5763266A (en) 1989-06-15 1998-06-09 The Regents Of The University Of Michigan Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells
DE3923279A1 (de) 1989-07-14 1990-01-18 Will W Prof Dr Minuth Minusheets ist ein neues produkt, um zellen in beliebigen behaeltnissen in hochdifferenzierter form auf einer moeglichst natuerlichen unterlage zu kultivieren
GB9120508D0 (en) * 1991-09-26 1991-11-06 Nycomed As Diagnostic agents
US5837477A (en) 1993-01-15 1998-11-17 The United States Of America As Represented By The Department Of Health And Human Services T cell receptor ligands and methods of using same
US5942607A (en) 1993-07-26 1999-08-24 Dana-Farber Cancer Institute B7-2: a CTLA4/CD28 ligand
US5985653A (en) 1995-06-07 1999-11-16 Aastrom Biosciences, Inc. Incubator apparatus for use in a system for maintaining and growing biological cells
US6096532A (en) 1995-06-07 2000-08-01 Aastrom Biosciences, Inc. Processor apparatus for use in a system for maintaining and growing biological cells
WO1997001304A1 (en) * 1995-06-29 1997-01-16 Mallinckrodt Medical, Inc. Radiolabeled apatite particles containing a paramagnetic ion
US5962319A (en) * 1997-05-19 1999-10-05 Bml, Inc. Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies

Also Published As

Publication number Publication date
KR20030032922A (ko) 2003-04-26
EP1257632B1 (en) 2007-09-12
DE60130435T2 (de) 2009-07-23
AU2001243288B2 (en) 2005-11-24
BR0108545A (pt) 2004-06-29
ES2302726T3 (es) 2008-08-01
CA2406864A1 (en) 2001-08-30
WO2001062895A3 (en) 2002-02-28
DE60130435D1 (de) 2007-10-25
ATE373078T1 (de) 2007-09-15
EP1257632A1 (en) 2002-11-20
AU4328801A (en) 2001-09-03
US6905874B2 (en) 2005-06-14
CN1419597A (zh) 2003-05-21
WO2001062895A2 (en) 2001-08-30
US20020058019A1 (en) 2002-05-16
IL151287A0 (en) 2003-04-10
IL151287A (en) 2009-06-15
HK1047770A1 (zh) 2003-03-07
MXPA02008265A (es) 2004-09-10
HK1052372A1 (zh) 2003-09-11
JP2004500095A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
DK1257632T3 (da) Samtidig stimulering og opkoncentrering af celler
WO2003067221A3 (en) Compositions and methods for restoring immune responsiveness in patients with immunological defects
FI963101A (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
RU2005137167A (ru) Композиции и способы для wt1 специфической иммунотерапии
WO1999000137A3 (en) Induction of an activated myeloid dendritic cell phenotype
WO2003086280A3 (en) Immunostimulatory g,u-containing oligoribonucleotides
EP1381280A4 (en) VIRAL VECTORS AND USE THEREOF IN THERAPEUTIC METHODS
PL374865A1 (en) Treatment of tnf alpha related disorders
NO20033812L (no) Acylerte piperidinderivater som melanokortin-4- reseptoragonister
WO2003106498A3 (en) HUMAN OX40 RECEPTOR AGONIST BINDING MOLECULES
EP1728863A3 (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency
PL343245A1 (en) Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
EP1385506A4 (en) ACYLATED PIPERID DERIVATIVES AS MELANOCORTIN-4 RECEPTORAGONISTS
SI1532131T1 (sl) Motilidne spojine
EP2311960A3 (en) Bv8 nucleic acids and polypeptides with mitogenic activity
EP1820514A3 (en) Therapeutic compositions that produce an immune response by altering the antigen
DK0809627T3 (da) Hidtil ukendte borneolderivater, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse
DK1196188T3 (da) VGF-selektive monoklonale antistoffer og deres anvendelse til behandling af VGF-relaterede lidelser
ATE380884T1 (de) Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.
UA38418A (uk) Засіб для стимуляції регенеративних процесів в інсулінпродукуючому апараті підшлункової залози
RU2000123854A (ru) Способ лечения дисциркуляторной атеросклеротической энцефалопатии
UA38284A (uk) Спосіб корекції дії барбітуратів
BR8301851U (pt) Aparelho de estimulação vibrotáctil dos pontos de acupuntura